CDCA5 has been ascertained in multiple cancers and participates in the PI3K/AKT pathway to drive breast cancer development, as well as promote prostate cancer progression via effects on the ERK signaling pathway [24, 25]. Here, CDCA5 is linked to prostate cancer.